Cooperative Agreement 2019ARBXK038

The U.S. Department of Health and Human Services, through the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment, awarded a $55,500,000 Project Grant (CFDA 93.243) to the American Academy of Addiction Psychiatry (AAAP) and its collaborative partners. The grant, titled "Opioid Response Network: Collaborating, Advancing, Responding, Educating (CARE Team)", will provide training and technical assistance to address opioid use disorder,...

This $13,718,085 Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of PF614-MPAR, an opioid analgesic with built-in abuse-deterrent and overdose protection features. The key product being developed is PF614-MPAR, a combination product comprising the TAAP-oxycodone prodrug PF614 and the trypsin inhibitor nafamostat. This novel formulation is designed to provide pain...

The Ohio Department of Health was awarded a $6 million project grant from the Department of Justice's Bureau of Justice Assistance under the Comprehensive Opioid, Stimulant, and other Substances Use Program to implement evidence-based substance use disorder treatment and harm reduction services in six counties. The three-year award will support expanding harm reduction activities and education targeting Black and Hispanic populations in high-risk areas; improving access to medication-assisted...

This $295,906 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate an opioid medication management system called the ADDINEX platform into a hospital pharmacy's workflows. The goal is to reduce opioid use by emergency department patients upon discharge. Key aspects include: Adapting the ADDINEX system, which uses secure dispensers and mobile app passcodes to control opioid access, to work...

This $1.4 million cooperative agreement from the Department of Justice Office of Justice Programs Bureau of Justice Assistance, under the Harold Rogers Prescription Drug Monitoring Program (CFDA 16.754), will fund four enforcement agents from the Ohio State Board of Pharmacy to conduct criminal investigations and analyze controlled substance prescription data from Ohio's prescription drug monitoring program (PDMP), known as the Ohio Automated Rx Reporting System (OARRS), from October 1, 2022...

The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...

The Madison County Sheriff's Office Offender Reentry Program Team will receive $998,934 over three years from the Department of Justice Office of Justice Programs Bureau of Justice Assistance under the Comprehensive Opioid, Stimulant, and other Substances Use Program (COSSUP) to implement a medication-assisted treatment (MAT) program in the county jail. The program aims to reduce opioid misuse and overdoses by providing injectable buprenorphine MAT to 20 high-risk incarcerated individuals per...

The Purchase District Health Department has been awarded a $1,000,000 Comprehensive Opioid, Stimulant, and Substance Use Program (CFDA 16.838) grant from the U.S. Department of Justice's Bureau of Justice Assistance. The 3-year project, which began on October 1, 2023, aims to implement partnerships between public health, public safety, and recovery communities to address the opioid and substance use disorder epidemic in 8 counties in western Kentucky. Key project activities include: 1)...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,902,673.00 to Rutgers, The State University of New Jersey to establish the OPRM1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management. The award period runs from September 30, 2024 to May 31, 2029. The key products and services...

The Orleans Parish District Attorney's Office will receive $1.3 million under a Project Grant award from the Department of Justice Office of Justice Programs Bureau of Justice Assistance Comprehensive Opioid, Stimulant, and other Substances Use Program (COSSUP) to establish the Metropolitan Overdose Data to Action Program (MODTAP). MODTAP will consolidate existing anti-opioid committees into a single coordinating body charged with collecting, reviewing, and disseminating overdose data from...